Loading organizations...
§ Private Profile · 1050 Waltham Street, Suite 301, Lexington, MA
Triana Biomedicines is a technology company.
Triana Biomedicines specializes in developing novel therapeutics by leveraging molecular glues to induce specific protein-protein interactions. Their proprietary technology identifies small molecules that can alter the function or degradation of disease target proteins by engaging the cell's ubiquitin-proteasome system. This platform allows the company to pursue previously undruggable targets, expanding therapeutic possibilities.
Formed to systematically harness molecular glues, the company tackles challenging disease targets. Key leadership includes CEO Dr. Patrick Trojer, who joined in November 2021. Dr. Trojer, a co-founder of Constellation Pharmaceuticals, brings significant oncology drug discovery pedigree, underscoring Triana's rational, target-first approach.
Triana Biomedicines concentrates its initial efforts on targeted protein degradation within oncology, aiming to deliver groundbreaking new cancer medicines. The company's long-term vision is to unlock the full potential of molecular glues, developing precision therapies that address critical unmet medical needs and transform patient lives.
Triana Biomedicines has raised $230.0M across 2 funding rounds.
Triana Biomedicines has raised $230.0M in total across 2 funding rounds.
Triana Biomedicines has raised $230.0M across 2 funding rounds. Most recently, it raised $120.0M Series B in December 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 3, 2025 | $120M Series B | Lorence KIM, Andrew Hedin | Atlas Venture, Finchley Healthcare Ventures, Invus, Lightspeed Venture Partners, RA Capital Management, Regeneron Ventures, Surveyor Capital, YK Bioventures | Announced |
| Apr 1, 2022 | $110M Series A | Atlas Venture, Shelley CHU | Agent Capital, Longwood Fund, Pfizer Venture Investments, Logos Capital, Joshua Resnick, Surveyor Capital | Announced |
Triana Biomedicines has raised $230.0M in total across 2 funding rounds.
Triana Biomedicines's investors include Lorence Kim, Andrew Hedin, Atlas Venture, Finchley Healthcare Ventures, Invus, Lightspeed Venture Partners, RA Capital Management, Regeneron Ventures, Surveyor Capital, YK Bioventures, Shelley Chu, Agent Capital.
Triana Biomedicines is a venture-backed biopharmaceutical company developing novel therapeutics using molecular glues—small molecules that promote protein-protein interactions to degrade or alter disease-causing proteins, targeting undruggable targets in oncology.[1][2][3][4] Headquartered in the greater Boston area (Waltham/Lexington, MA), it serves patients with hard-to-treat cancers by building a discovery platform powered by structural biology, AI, computational tools, and custom chemical libraries, with an initial focus on targeted protein degradation (TPD) via the ubiquitin-proteasome system.[1][3][4] Founded in 2020 with 11-50 employees, the company has raised $110M in Series A funding in March 2022 from RA Capital Management and Atlas Venture, remaining in the research and development (R&D) stage with an undisclosed lead product.[3][4]
Triana Biomedicines was founded in 2020 in Waltham, MA, seeded by leading biotech investors RA Capital Management and Atlas Venture.[3][4] Key leaders include Patrick Trojer, PhD, President & CEO, bringing expertise in drug discovery innovation, and Christopher O’Donnell, PhD from Pfizer Ventures on the board, alongside clinical operations veteran Mr. Marsh, who has advanced three approved products including ZILBRYSQ®.[1] The idea emerged from recognizing that ~85% of disease targets are undruggable with traditional methods; Triana's rational, target-first platform identifies molecular glues to "glue" targets to E3 ubiquitin ligases for degradation, unlocking new cancer therapies.[1][3][4] Early traction includes rapid platform buildout and $110M funding, positioning it for transformative small-molecule drug discovery.[4]
Triana rides the targeted protein degradation (TPD) wave, a booming trend in biotech where molecular glues and PROTACs expand the druggable proteome beyond traditional inhibitors, tackling ~85% of previously undruggable targets.[1][4] Timing is ideal amid AI-driven drug discovery advances and post-2020 biotech funding surge, with greater Boston's ecosystem (MassBio member) providing talent and infrastructure.[3] Market forces like rising cancer prevalence and demand for precision oncology favor Triana, as its platform influences small-molecule paradigms by enabling E3 ligase-mediated degradation for transformative therapies.[1][3] It contributes to the ecosystem by pioneering glues, inspiring similar platforms (e.g., RNA splicing or epigenetic editors in peers), and seeding innovation via top-tier VCs.[2][3]
Triana is poised to advance its oncology pipeline into clinic, leveraging its platform for first-in-class molecular glues against high-value targets, with potential expansion to other diseases.[1][3] Trends like AI-enhanced structural prediction and combo therapies with immunotherapies will accelerate progress, while VC backing supports nimble scaling amid biotech M&A waves.[4] Its influence may grow through partnerships, IP (2 patents filed), or acquisitions, solidifying molecular glues as a core drug modality and transforming undruggable targets into patient wins—echoing its mission to unlock precision medicines.[1][2]